Recent Updates
Recently added Catalysts
A Positive Sentiment

Agilent Completes Acquisition of Proscia

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Agilent Technologies Inc. has completed its acquisition of Proscia, a digital-pathology software provider, for $240 million in cash. The deal includes an additional $30 million contingent on future performance milestones. This acquisition is expected to strengthen Agilent's position in the clinical and life sciences sectors.

Market Sentiment Analysis

POSITIVE FACTORS

  • Agilent successfully completed the acquisition.
  • Proscia is a leader in digital-pathology software.
  • The acquisition enhances Agilent's offerings in clinical and life sciences.
  • Potential for additional $30 million based on performance milestones.

Full Press Release Details

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Proscia®, a leading provider of digital-pathology software for clinical and life-sciences customers. Under the terms of the transaction, Agilent acquired Proscia for $240 million in cash at closing, with up to an additional $30 million payable based on the achievement of future performance milestones. Following the closing of the transact

Frequently Asked Questions

What was the acquisition cost for Proscia?

Agilent acquired Proscia for $240 million in cash.

Is there a performance-based payment in the deal?

Yes, up to an additional $30 million is payable based on performance milestones.

What does Proscia specialize in?

Proscia is a leading provider of digital-pathology software.

How will this acquisition benefit Agilent?

It will enhance Agilent's offerings in clinical and life sciences.

ShareAdd on Google
Tags: A Agilent Proscia digital pathology acquisition clinical software
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$1758M liquidity · $0M/mo burn
Low dilution risk